AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 37101272
Drug: High-flow nasal
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-flow nasal oxygen therapy (HFNC-O)
Trial: 37101768
Drug: Erdafitinib (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erdafitinib (8 mg/d continuous in 28-d cycles, uptitration to 9 mg/d if serum phosphate <5.5 mg/dl)
Trial: 37102598
Drug: KCd (weekly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KCd (weekly carfilzomib 70 mg/m2, cyclophosphamide, and dexamethasone)
Trial: 37103493
Drug: StressProffen-CBI (Cognitive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: StressProffen-CBI (Cognitive Behavioral Therapy Intervention)
Trial: 37103532
Drug: Oral GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral GnRH antagonists (elagolix 300 mg twice daily with estradiol 1 mg and norethindrone 0.5 mg; relugolix 40 mg once daily with estradiol 1 mg and norethindrone 0.5 mg)
Trial: 37103532
Drug: Oral GnRH
RxNorm normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral GnRH antagonists with menopausal replacement-level steroid hormones
Trial: 37103915
Drug: Lumateperone, dosage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lumateperone, dosage and duration not available
Trial: 37104481
Drug: Transdermal measurement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal measurement of FITC-sinistrin
Trial: 37104748
Drug: Dose-escalated radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-escalated radiotherapy (RT) alone
Trial: 37104748
Drug: Dose-escalated radiotherapy
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dose-escalated radiotherapy (RT) with short-term androgen deprivation (STAD)
Trial: 37104758
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy of margetuximab and pembrolizumab
Trial: 37105210
Drug: Non-allogeneic HSCT
RxNorm normalized name: Allogeneic processed thymus tissue
DrugBank: Allogeneic processed thymus tissue (DB16736)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-allogeneic HSCT therapy
Trial: 37105689
Drug: Immunotherapy (specific
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy (specific types not detailed)
Trial: 37105693
Drug: COVID-19 convalescent
RxNorm normalized name: COVID-19 convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: COVID-19 convalescent plasma (CCP) with very high neutralising antibody titre administered within 7 days of symptom onset plus standard of care
Trial: 37106220
Drug: Mechanical stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical stimulation of the efferent limb with 500 ml of saline chloride solution mixed with a thickening agent (Resource) for 2 weeks before ileostomy reversal.
Trial: 37106319
Drug: M-TAPA block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-TAPA block (bupivacaine 0.25%, 25 ml)
Trial: 37106319
Drug: OSTAP block
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: OSTAP block (bupivacaine 0.25%, 25 ml)
Trial: 37106343
Drug: General anesthesia
RxNorm normalized name: Ethers for general anesthesia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General anesthesia (intravenous propofol/ketamine/sodium thiopental)
Trial: 37106559
Drug: Transdiagnostic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdiagnostic group cognitive behaviour therapy (CBT)
Trial: 37106559
Drug: Diagnosis-specific group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diagnosis-specific group cognitive behaviour therapy (CBT)
Trial: 37107903
Drug: Usual clinical
RxNorm normalized name: DuoCare Clinical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual clinical treatment (UCT) without technology
Trial: 37108484
Drug: Mediterranean diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet (MD), specific details on dosage and duration not available.
Trial: 37109303
Drug: Oral sodium-chloride
RxNorm normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral sodium-chloride capsules
Trial: 37111136
Drug: Low-dose (LD)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose (LD) supplement containing 440 mg of Fucoxanthin and Guarana
Trial: 37111382
Drug: Immune checkpoint
RxNorm normalized name: Immune Globulin
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immune checkpoint inhibitors (ICIs) treatment
Trial: 37113674
Drug: DREAMS 3G
RxNorm normalized name: Dream Pure BB
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DREAMS 3G (third-generation drug-eluting resorbable magnesium scaffold)
Trial: 37114054
Drug: EP/EC plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP/EC plus PD-L1 inhibitor (historical control)
Trial: 37114918
Drug: Implant-Based Reconstruction
RxNorm normalized name: CONSTRICTION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implant-Based Reconstruction (IBR)
Trial: 37115054
Drug: Pregabalin sustained-release
RxNorm normalized name: pregabalin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin sustained-release (SR) tablet (150 mg once a day)
Trial: 37115054
Drug: Pregabalin immediate-release
RxNorm normalized name: pregabalin Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregabalin immediate-release (IR) capsule (75 mg twice a day)
Trial: 37115132
Drug: No-implant interatrial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No-implant interatrial shunt
Trial: 37115135
Drug: Goal doses
RxNorm normalized name: OCTINOXATE 7.5 g in 100 g / OXYBENZONE 6 g in 100 g / PADIMATE O 8 g in 100 g TOPICAL LIPSTICK [Goofy Sun Smacker SPF 24 Berry Goal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal doses of beta-blockers
Trial: 37115135
Drug: Goal doses
RxNorm normalized name: OCTINOXATE 7.5 g in 100 g / OXYBENZONE 6 g in 100 g / PADIMATE O 8 g in 100 g TOPICAL LIPSTICK [Goofy Sun Smacker SPF 24 Berry Goal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Goal doses of ACEIs/ARBs/ARNIs
Trial: 37115464
Drug: Mirogabalin 5-10
RxNorm normalized name: mirogabalin
DrugBank: Mirogabalin (DB11825)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Mirogabalin 5-10 mg BID for 4 weeks, then 15 mg BID for 47 weeks, followed by tapering to once daily for 1 week.
Trial: 37115464
Drug: Mirogabalin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mirogabalin treatment for CNePSCI, CPSP, and CNePPD.
Trial: 37115514
Drug: Selumetinib (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (continuous dosing, 1 cycle = 28 days)
Trial: 37115514
Drug: Selumetinib (continuous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selumetinib (continuous dosing)
Trial: 37115905
Drug: First ART
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First ART discontinuation and reaching a first undetectable pVL
Trial: 37115908
Drug: Standard medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard medical therapy plus growth hormone (GH) therapy
Trial: 38536106
Drug: Photobiomodulation Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photobiomodulation Therapy
Trial: 37116228
Drug: Kukoamine B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kukoamine B (KB) at doses of 0.06, 0.12, or 0.24 mg/kg every 8 hours for 7 days
Trial: 37116523
Drug: Quizartinib plus
RxNorm normalized name: quizartinib
DrugBank: Quizartinib (DB12874)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Quizartinib plus chemotherapy
Trial: 37116825
Drug: Curcumin (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin (600 mg Theracurmin HP daily for 30 days)
Trial: 37116825
Drug: Placebo (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (daily for 30 days)
Trial: 37117085
Drug: Pharmaceutical therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical therapy
Trial: 37118696
Drug: Cough desensitization
RxNorm normalized name: Pediaclear Cough
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cough desensitization treatment (CDT)
Trial: 37118703
Drug: Elevated cTnT
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Elevated cTnT (≥ 14 ng/L) one year after the primary event
Trial: 37119051
Drug: Enzalutamide (enza)
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide (enza) + Leuprolide Acetate (LA) 160 mg/day
Trial: 37119051
Drug: Enzalutamide monotherapy
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide monotherapy (mono)
Trial: 37119829
Drug: Urinary DKK3
RxNorm normalized name: Urinary hCG
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Urinary DKK3 above the median (>1689 pg/mg creatinine)
Trial: 37119829
Drug: Intensified blood
RxNorm normalized name: dragon's blood extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensified blood pressure control in children with urinary DKK3 >1689 pg/mg creatinine
Trial: 37119868
Drug: Integrated treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Integrated treatment for depression and smoking (12-week intervention)
Trial: 37120027
Drug: Routine radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine radiation therapy with LLNs inside the clinical target volume (CTV)
Trial: 37120027
Drug: Routine radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine radiation therapy with LLNs outside the clinical target volume (CTV)
Trial: 37120027
Drug: Routine radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine radiation therapy with LLNs receiving ≥95% of planned dose
Trial: 37120027
Drug: Routine radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Routine radiation therapy with LLNs receiving <95% of planned dose
Trial: 37120027
Drug: Dose escalation
RxNorm normalized name: PALFORZIA Initial Dose Escalation KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation of 60 Gy
Trial: 37120509
Drug: Pediatric Medication
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pediatric Medication Therapy Management (pMTM) intervention
Trial: 37120593
Drug: Venetoclax (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Venetoclax (100 mg on day 1, 200 mg on day 2, and 400 mg on days 3-14) combined with azacitidine (75 mg/m2) and homoharringtonine
Trial: 37120671
Drug: SRA737 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRA737 800 mg QD
Trial: 37120671
Drug: SRA737 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRA737 1000 mg QD
Trial: 37120671
Drug: SRA737 1300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRA737 1300 mg QD
Trial: 37120671
Drug: SRA737 monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SRA737 monotherapy
Trial: 37120736
Drug: Atorvastatin 40
RxNorm normalized name: atorvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin 40 mg once-daily
Trial: 37120902
Drug: Daily enteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily enteral lipid supplementation with arachidonic acid (AA):docosahexaenoic acid (DHA) (100:50 mg/kg/day)
Trial: 37120902
Drug: Intravenous lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lipid emulsion containing olive oil:soybean oil (4:1)
Trial: 37121237
Drug: Indobufen (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen (100 mg tablet twice per day)
Trial: 37121237
Drug: Aspirin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin (100 mg tablet once per day)
Trial: 37121237
Drug: Indobufen and
RxNorm normalized name: indobufen
DrugBank: Indobufen (DB12545)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indobufen and Aspirin
Trial: 37121390
Drug: Referral to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Referral to the Mid-Ohio Farmacy (weekly access to fresh produce)
Trial: 37122050
Drug: Weight-based HFNC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weight-based HFNC (max flow of 2 L/kg per minute)
Trial: 37122050
Drug: Standard HFNC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard HFNC (max flow of 8 L per minute)
Trial: 37122809
Drug: SB2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SB2 treatment in IFX-naïve patients
Trial: 37122809
Drug: SB2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SB2 treatment in IFX ref patients
Trial: 37122809
Drug: SB2 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SB2 treatment in IFX bs patients
Trial: 37124199
Drug: Machine learning-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Machine learning-based detection system for medication errors
Trial: 37124726
Drug: Testosterone enanthate
RxNorm normalized name: Testosterone Enanthate
DrugBank: Testosterone enanthate (DB13944)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Testosterone enanthate (TE), 75 mg intramuscularly/month for 6 months
Trial: 37124726
Drug: Testosterone undecanoate
RxNorm normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Testosterone undecanoate (TU), 250 mg intramuscularly every 3 months for 6 months
Trial: 37124732
Drug: ω3-LCPUFAs (500-mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω3-LCPUFAs (500-mg soft capsules, 0.100 g/kg of body weight/day for three months)
Trial: 37125397
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose vitamin D (5000 IU/day)
Trial: 37125397
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose vitamin D (600 IU/day)
Trial: 37125459
Drug: Daprodustat 4
RxNorm normalized name: daprodustat 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daprodustat 4 mg tablets manufactured via twin-screw wet granulation (process 1)
Trial: 37125459
Drug: Daprodustat tablets
RxNorm normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Daprodustat tablets manufactured via process 1 (1, 2, 4, 6, and 8 mg)
Trial: 37125459
Drug: Daprodustat tablets
RxNorm normalized name: daprodustat
DrugBank: Daprodustat (DB11682)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Daprodustat tablets manufactured via process 2 (1, 2, 4, 6, and 8 mg)
Trial: 37125500
Drug: L-citrulline +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-citrulline + Glutathione (Setria Performance Blend: SPB; L-citrulline [2 g] + glutathione [200 mg], 6 capsules)
Trial: 37125500
Drug: Placebo (PL;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PL; 3.1 g cellulose, 6 capsules)
Trial: 37125884
Drug: Psychosocial stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psychosocial stimulation intervention consisting of weekly play sessions at home for 9 months, along with iron treatment for 6 months for IDA group.
Trial: 37126069
Drug: Positron emission
RxNorm normalized name: propofol lipid emulsion Injection [Propoven]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Positron emission tomography/CT after intravenous administration of 296±20% MBq
Trial: 37126332
Drug: Xuebijing injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xuebijing injection (100 mL, intravenous infusion every 12 hours for 5 days)
Trial: 37126332
Drug: Placebo (volume-matched
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (volume-matched saline, intravenous infusion every 12 hours for 5 days)
Trial: 37126338
Drug: Multimodal transitional
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Multimodal transitional care intervention including systematic medication reconciliation, a 15-minute patient education session with teach-back, a planned first follow-up visit with their primary care physician, and postdischarge follow-up telephone calls at 3 and 14 days.
Trial: 37126399
Drug: Intranasal testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intranasal testosterone gel 11 mg 3 times daily
Trial: 37126399
Drug: Intramuscular testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular testosterone cypionate 200 mg every 2 weeks
Trial: 37126739
Drug: Omega-3 supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omega-3 supplementation (600 mg EPA and 300 mg DHA, twice daily)
Trial: 37126770
Drug: Lenalidomide (regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide (regimen A, low-dose 20 mg/m2)
Trial: 37127045
Drug: Fractional dose
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional dose (one-fifth of the standard dose) of 17D-213 yellow fever vaccine
Trial: 37127047
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of 17D-213 yellow fever vaccine
Trial: 37127047
Drug: Fractional dose
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fractional dose (one-fifth) of 17D-213 yellow fever vaccine
Trial: 37127210
Drug: Advanced oral
RxNorm normalized name: Imodium Advanced Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced oral hygiene regimen (antibacterial mouth wash, dental floss, antibacterial toothpaste, power toothbrush, intensive oral hygiene education)
Trial: 37127210
Drug: Usual oral
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual oral hygiene care (standard oral home care instructions and regimen)
Trial: 37127210
Drug: Advanced oral
RxNorm normalized name: Imodium Advanced Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced oral hygiene regimen
Trial: 37127210
Drug: Usual oral
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual oral hygiene care
Trial: 37127210
Drug: Advanced oral
RxNorm normalized name: Imodium Advanced Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Advanced oral hygiene regimen among unemployed participants with less favorable socioeconomic status
Trial: 37127210
Drug: Usual oral
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual oral hygiene care among unemployed participants with less favorable socioeconomic status
Trial: 37127526
Drug: Sabin strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sabin strain inactivated poliovirus vaccine (sIPV)
Trial: 37127526
Drug: Wild strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wild strain poliovirus vaccine (wIPV)
Trial: 37127558
Drug: vonoprazan 20
RxNorm normalized name: vonoprazan 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: vonoprazan 20 mg for 4-8 weeks, then 10 mg for maintenance
Trial: 37127558
Drug: lansoprazole 30
RxNorm normalized name: lansoprazole 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lansoprazole 30 mg for 4-8 weeks, then 15 mg for maintenance
Trial: 37127632
Drug: HEMO2life® (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HEMO2life® (1 g/l preservation solution)
Trial: 37127632
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (routine preservation solution)
Trial: 37127657
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg naldemedine daily for 12 months
Trial: 37127754
Drug: CBP/p300 HAT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBP/p300 HAT inhibitors
Trial: 37127754
Drug: Investigational KAT6A/B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Investigational KAT6A/B HAT inhibitor
Trial: 37129110
Drug: Recast therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recast therapy embedded in a first-grade science curriculum
Trial: 37129110
Drug: Recast therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Recast therapy
Trial: 37129155
Drug: Capecitabine maintenance
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Capecitabine maintenance after XELOX chemotherapy
Trial: 37129155
Drug: Observation after
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Observation after XELOX chemotherapy